로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CEACAM-8

CEACAM-8

요약

Name:Non specific cross-reacting antigen 95
Target Synonym:Non-specific cross-reacting antigen NCA-95,CGM6,Carcinoembryonic Antigen Gene Family Member 6,CD66b Antigen,NCA-95,CD67,Carcinoembryonic antigen CGM6,CD66b,CEACAM8,Carcinoembryonic Antigen Related Cell Adhesion Molecule 8,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8,CD67 Antigen,CEA Cell Adhesion Molecule 8
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

CE8-H82E9-SPR
 CEACAM-8 SPR

Biotinylated Human CEACAM-8, His,Avitag (Cat. No. CE8-H82E9) immobilized on SA Chip can bind Human CEACAM-6, His Tag (Cat. No. CE6-H5223) with an affinity constant of 4.57 μM as determined in a SPR assay (Biacore 8K) (QC tested).

CE8-H5224-ELISA
 CEACAM-8 ELISA

Immobilized Human CEACAM-8, His Tag (Cat. No. CE8-H5224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-6, His,Avitag (Cat. No. CE6-H82E7) with a linear range of 0.078-1.25 μg/mL (QC tested).

Synonym Name

CEACAM8,CD66b,CD67,CGM6,NCA-95

Background

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Besilesomab BW-250-183; 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx Approved Cis Bio International Sa Scintimun EU Osteomyelitis Cis Bio International Sa 2010-01-11 Osteomyelitis Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
90Y-DTPA-besilesomab TLX-66 Phase 2 Clinical Telix Pharmaceuticals Ltd Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell Details

This web search service is supported by Google Inc.

totop